Диссеминированный рак почки: факторы прогноза, лечение и перспективы

1. Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями и смертность от них населения стран СНГ в 2002 г. — М. — 2002.

2. В.Б. Матвеев. Хирургическое лечение осложненного венозной инвазией метастатического рака почки. — Автореф. дис. докт. мед. наук. — М. — 2002. — С. 21.

3. Д.А. Носов. Особенности клинического течения и современные возможности лекарственного лечения диссеминированного рака почки. Автореф. дис. канд. мед. наук. — М. — 2000.

4. Д.А. Носов, В.Б. Матвеев. Тактика лечения больных с единичными метастазами почечно-клеточного рака в легкие. // Вестник РОНЦ. — 2005 (в печати).

5. Assikis V., Daliani D., Pagliaro L. et al. Phase II study of autologous tumor derived heat shock protein-peptide complex vaccine for patients with metastatic renal cell carcinoma. Proc. ASCO. — 2003. — V.22: 386 (abst 1552).

6. Atzpodien J., Kirchner H., Illiger H.J., Metzner B. et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. // Br. J. Cancer. — 2001. — Oct 19; 85(8): 1130—6.

7. Atzpodien J., Kirchner H., Jonas U., Bergmann L. et al. Interleukin-2-and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). // J. Clin. Oncol. — 2004. — V22(7): 1188—94.

8. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2. // Cancer. — 1997. — V. 80. — P. 1198—11220.

9. Dawson N., Guo C., Zak R. et al. A phase II trial of ZD1839 in stage IV and recurrent renal cell carcinoma. Proc. ASCO. — 2003, 22: 404 (abst. 1623).

10. Drucker B., Bacik J., Ginsberg M. et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. // Invest. New Drugs. — 2003, 21:341—345.

11. Flanigan R., Salmon S., Blumenstein B. et al. Nephrectomy followed by interferon alfa-2b comgared with interferon alfa-2b alone for metastatic renal cell cancer. // N. Engl. J. Med. — 2001. — V345: 1655—1659.

12. Fyfe G., Fisher R.I., Rosenberg S.A. et al. Results of treatment 255 patients with metastatic RCC who received high dose recombinant interleukin-2 therapy. // J. Clin. Oncol. — 1995. — V.13: 688—696.

13. Geertsen P.F., Gore M.E., Negrier S. et al. Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma. // Br. J. Cancer. — 2004. 22; 90(6):1156—62.

14. Gordon M.S., Manola J., Fairclough D. et al. Low dose interferon-alpha2b (IFN) + thalidomide (T) in patients (pts) with previously untreated renal cell cancer (RCC). Improvement in progression-free survival (PFS) but not quality of life (QOL) or overall survival (OS). A phase III study of the Eastern Cooperative Oncology Group (E2898). Proc. ASCO. — 2004, 23: 384 (abst. 4516).

15. Hainsworth J.D., Sosman J.A., Spigel D.R. et al. Phase II trial of bevacizumab and erlotinib in patients with metastatic renal cell carcinoma (RCC). Proc. ASCO. — 2004, 23: 381 (abstract 4502).

16. Henriksson R., Nilsson S., Collen S. et al. Survival in renal cell carcinoma — a randomized evaluation of tamoxifen vs interleukin-2, a-interferon (leucocyte) and tamoxifen. // Br. J. Cancer. — 1998. — V. 77 (8): 1311—1317.

17. Horoszewicz J.S., Murphy G.P. An assesment of the current use of human interferons in therapy of urological cancers. // J. Urology. — 1989. — V. 142: 1173—1180.

18. Maisey N.R., Hall K., Lee C. et al. Infliximab: A phase II trial of the tumour necrosis factor (TNFa) monoclonal anti-body in patients with advanced renal cell cancer (RCC). Proc. ASCO. — 2004, 23: 384 (abst. 4514).

19. McDermott D., Regan M., Clark J. et al. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma. // J. of Clinical Oncology. — 2005. — V. 23. No 1: 133—141.

20. Mickisch G.N., Garin A. Value of tumorenephrectomy in conjunction with immunotherapy in metastatic renal cell carcinoma: results of a randomized phase III trial (EORTC30947). // Eur. Urol. — 2000. — V. 37. — Suppl 2. — Р. 55.

21. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma review article. // N. Engl. J. Med. — 1996. — V.12: 865—75.

22. Motzer R.J., Masumdar M., Bacic J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. // J. Clin. Oncology. — 1999. — V.17 (8): 2530—2540.

23. Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. // J. Clin. Oncol. — 2002. — Jan. 1. — V20(1): 289—96.

24. Motzer R.J., Rini B.I., Michaelson M.D. et al. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. Proc. ASCO. — 2004, 23: 381 (abst. 4500).

25. Negrier S., Caty A., Lesimple T., Douillard J..Y. et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon-alfa with or without fluorouracil. Groupe Francais d’Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. // J. Clin. Oncol. — 2000. — Dec. 15; 18(24): 4009—15.

26. Negrier S., Escudier B., Lasset C. et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. // N. Engl. J. Med. — 1998. — Apr 30;338(18):1272—8.

27. Palmer P.A., Atzpodien J., Philip T., Negrier S. et al. A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alfa in patients with advanced RCC. Cancer Biotherapy. — 1993.123—136.

28. Piltz S., Meimarakis G., Wichmann M. et al. Long-term results after pulmonary resection of renal cell carcinoma metastases. // Ann Thorac Surgery. — 2002. — V.73: 1082—87.

29. Ratain M.J., Flaherty K.T., Stadler W.M. et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). — Proc. ASCO. — 2004, 23: 381 (abst. 4501).

30. Savage P.D., Muss H.B. Renal cell cancer. Philadelphia: J.B. Lippincott Co. — 1995. 373—387.

31. Smith J.W., Yo K.-J., Dutcher J. et al. Update of a phase I study of intravenous CCI-779 given in combination with interferon-a to patients with advanced renal cell carcinoma. Proc. ASCO. — 2004, 23: 384 (abst. 4513).

32. Yang J.C., Haworth L., Sherry R.M. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. // N. Engl. J. Med. — 2003. 349: 427—434.

33. Yang J., Sherry R., Steinberg S. et al. Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer. // J. Clin. Oncol. — 2003. — V. 21, 16: 3127—3132.